BioMarin Pharmaceutical Inc. (BMRN) Granted Accelerated Assessment of Roctavian - Truist Securities

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $125.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after the comapny reported that the EMA has granted its request for accelerated assessment of roctavian. Accelerated assessment (equivalent to FDA's priority review) is expected to lead to CHMP opinion in 150 days vs. 210 days for regular review; with a standard timetable. The CHMP opinion is expected in 2Q2022.

The analyst stated "We see this as a positive not only from the perspective of reduced time for approval/ launch, but also as an acknowledgement of regulatory authority of the strength of the data and the unmet need in severe Hem A patients. Co. still on track to submit 1 year pivotal data to the EMA for review in June 2021; this continues to be in-line with company's guidance for a 2Q submission."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $78.10 yesterday.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald